UY30935A1 - Combinacion:-antagonista del receptor de quimioquina 1 (ccr1) -agonista del receptor de glucocorticoides- opcionalmente agonista b(beta)2, -composicion farmacéutica conteniéndola -aplicaciones. - Google Patents

Combinacion:-antagonista del receptor de quimioquina 1 (ccr1) -agonista del receptor de glucocorticoides- opcionalmente agonista b(beta)2, -composicion farmacéutica conteniéndola -aplicaciones.

Info

Publication number
UY30935A1
UY30935A1 UY30935A UY30935A UY30935A1 UY 30935 A1 UY30935 A1 UY 30935A1 UY 30935 A UY30935 A UY 30935A UY 30935 A UY30935 A UY 30935A UY 30935 A1 UY30935 A1 UY 30935A1
Authority
UY
Uruguay
Prior art keywords
agonist
combination
beta
glucocorticoid receptor
optionally
Prior art date
Application number
UY30935A
Other languages
English (en)
Inventor
John Mo
Marguerite Mensonides-Harsema
Thomas G Hansson
Tomas Eriksson
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of UY30935A1 publication Critical patent/UY30935A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A una combinacion de dosis terapéuticamente efectiva de : (a) un primer ingrediente activo, que es un compuesto de formula (I) o una sal farmacéuticamente aceptable del mismo; y (b) un segundo indgrediente activo, que es un agonista del receptor de glucocorticoides; y opcionalmente, (c) un tercer ingrediente activo, que es un agonista B(Beta)2. B Composiciones farmacéuticas que comprenden dicha combinacion C Métodos de tratamiento de enfermedades de las vías respiratorias, especialmente la enfermedad pulmonar obstructiva cronica (EPOC) y asma, D Kit comprendiendo combinacion y uso de dicho kit en el tratamiento de dichas enfermedades.
UY30935A 2007-02-23 2008-02-22 Combinacion:-antagonista del receptor de quimioquina 1 (ccr1) -agonista del receptor de glucocorticoides- opcionalmente agonista b(beta)2, -composicion farmacéutica conteniéndola -aplicaciones. UY30935A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US89124407P 2007-02-23 2007-02-23

Publications (1)

Publication Number Publication Date
UY30935A1 true UY30935A1 (es) 2008-09-30

Family

ID=39710315

Family Applications (1)

Application Number Title Priority Date Filing Date
UY30935A UY30935A1 (es) 2007-02-23 2008-02-22 Combinacion:-antagonista del receptor de quimioquina 1 (ccr1) -agonista del receptor de glucocorticoides- opcionalmente agonista b(beta)2, -composicion farmacéutica conteniéndola -aplicaciones.

Country Status (8)

Country Link
US (1) US20110124613A1 (es)
EP (1) EP2120935A4 (es)
AR (1) AR065453A1 (es)
CL (1) CL2008000539A1 (es)
PE (1) PE20090491A1 (es)
TW (1) TW200848035A (es)
UY (1) UY30935A1 (es)
WO (1) WO2008103126A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101553493B (zh) * 2006-07-19 2012-07-04 阿斯利康(瑞典)有限公司 三环螺哌啶化合物、它们的合成和它们作为趋化因子受体活性调节剂的用途
UY32521A (es) * 2009-04-03 2010-10-29 Astrazeneca Ab Combinación para emplear en el tratamiento de enfermedades respiratorias
WO2012163848A1 (en) 2011-05-27 2012-12-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of crohn's disease
CA2852160A1 (en) 2011-10-28 2013-05-02 Galderma Research & Development New leukocyte infiltrate markers for rosacea and uses thereof
US10752588B2 (en) 2014-12-19 2020-08-25 The Broad Institute, Inc. Dopamine D2 receptor ligands
US10633336B2 (en) 2014-12-19 2020-04-28 The Broad Institute, Inc. Dopamine D2 receptor ligands
GB201918692D0 (en) 2019-12-18 2020-01-29 Cambridge Entpr Ltd Treatment and prognosis of pancreatic cancer

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2373186A (en) * 2001-02-23 2002-09-18 Astrazeneca Ab Pharmaceutical combinations of a CCR3 antagonist and a compound which is usefulreatment of asthma, allergic disease or inflammation
GB0207436D0 (en) * 2002-03-28 2002-05-08 Glaxo Group Ltd Novel compounds
SE0202133D0 (sv) * 2002-07-08 2002-07-08 Astrazeneca Ab Novel compounds
SE0303090D0 (sv) * 2003-11-20 2003-11-20 Astrazeneca Ab Novel compounds
SE0303280D0 (sv) * 2003-12-05 2003-12-05 Astrazeneca Ab Novel compounds
SE0303541D0 (sv) * 2003-12-22 2003-12-22 Astrazeneca Ab New compounds
TW200744612A (en) * 2005-08-26 2007-12-16 Astrazeneca Ab New combination
MX2008002320A (es) * 2005-08-26 2008-03-14 Astrazeneca Ab Combinacion de compuestos que pueden ser utilizados en el tratamiento de enfermedades respiratorias, especialmente enfermedad pulmonar obstructiva cronica y asma.
CN101553493B (zh) * 2006-07-19 2012-07-04 阿斯利康(瑞典)有限公司 三环螺哌啶化合物、它们的合成和它们作为趋化因子受体活性调节剂的用途

Also Published As

Publication number Publication date
EP2120935A1 (en) 2009-11-25
TW200848035A (en) 2008-12-16
WO2008103126A1 (en) 2008-08-28
US20110124613A1 (en) 2011-05-26
CL2008000539A1 (es) 2008-10-10
EP2120935A4 (en) 2011-06-22
PE20090491A1 (es) 2009-05-31
AR065453A1 (es) 2009-06-10

Similar Documents

Publication Publication Date Title
JP2010132695A5 (es)
UY30935A1 (es) Combinacion:-antagonista del receptor de quimioquina 1 (ccr1) -agonista del receptor de glucocorticoides- opcionalmente agonista b(beta)2, -composicion farmacéutica conteniéndola -aplicaciones.
RS52940B (en) PHARMACEUTICAL FORMULATIONS OF SOLUTION FOR MEASURED DOSES OF PRESSURE INHALATORS
BRPI0515103A (pt) composição farmacêutica, inalador, processos para preparar o mesmo, e uma composição farmacêutica, e, uso de uma composição farmacêutica
NZ600790A (en) Combination therapy for copd
UY29085A1 (es) Derivados de pirimidina 4-sulfonamido sustituidos, compuestos intermedios para su preparación, procedimientos de preparación, composiciones medicinales conteniéndolos y aplicaci0nes
BR112015029512A2 (pt) derivados de pirazolopirrolidina e seu uso no tratamento de doenças
ECSP055855A (es) Medicamentos en polvo para inhalación que contiene una sal de tiotropio y salmeterolxinafoato
PE20060826A1 (es) Derivado oleofinico de 8-azoniabiciclo[3.2.1]octano y combinacion farmaceutica que lo comprende
CY1108978T1 (el) Συνδυασμος ενωσεων μεθυλξανθινης και στεροειδων για να θεραπευονται χρονιες αναπνευστικες ασθενειες
ECSP088974A (es) Derivados de imidazol pirimidina para el tratamiento de enfermedades relacionadas con la glicógeno sintasa quinasa (gsk3)
DOP2005000039A (es) Hidrocloruro de [4-(5-aminometil-2-fluoro-fenil)- piperidin-1-il]-(4-bomo-3-metil-5-propoxi-tiofen-2-il)-metanona como un inhibidor de la triptasa de mastocitos
UY31687A1 (es) Nueva dosificacion y formulacion
RU2013104401A (ru) Фармацевтический препарат, содержащий ингибитор фосфодиэстеразы
JP2008540506A5 (es)
ECSP066544A (es) Nuevas sales de tiotropio, procedimientos para su preparación, así como formulaciones medicamentosas que las contienen
PE20091392A1 (es) Composiciones farmaceuticas como agentes antiinflamatorios
EA200870302A1 (ru) 1,3-диоксанкарбоновые кислоты
MX2009008363A (es) Combinacion de un antagonista de receptor muscarinico y un agonista de receptor adrenergico beta 2.
CY1114163T1 (el) Μεθοδοι χρησεως ανταγωνιστων αγγειοπιεσινης με παραγοντες χημειοθεραπειας ανθρακυκλινης για να μειωνεται καρδιοτοξικοτητα ή/και να βελτιωνεται επιβιωση
NZ625592A (en) Compositions and methods for the treatment of hepatic diseases and disorders
JOP20200314A1 (ar) تركيبات صيدلانية مستقرة لأجهزة إستنشاق جرعات مضغوطة معايرة الجرعة
DOP2014000271A (es) Nueva forma de dosificacion y formulacion de abediterol
ECSP088287A (es) Una combinación de compuestos que puede ser utilizada en el tratamiento de enfermedades respiratorias, especialmente enfermedad pulmonar obstructiva crónica (epoc) y asma
EA201590019A1 (ru) Ингаляторы сухого порошка, содержащие носитель, отличный от лактозы

Legal Events

Date Code Title Description
DESI Application deemed to be withdrawn

Effective date: 20120612